← All trials
NCT04675827
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Jun 30, 2027
- Completion date
- Mar 31, 2029
- First posted
- Dec 19, 2020
- Last posted
- Jun 8, 2021
- Enrollment
- 1065
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Free University of BrusselsLead sponsor
- University of MilanCollaborator
- RocheCollaborator
- Free University of BrusselsStudy chair
- Curie InstituteCollaborator
- International Drug Development InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.